PeterWeidenMD

Neuropsychiatry, Psychopharmacology, Clinical Pharmacology

Clinical Professor of Psychiatry (Voluntary) Renaissance School of Medicine at Stony Brook University

Dr. Weiden is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Columbia University Mailman School of Public HealthMS, Psychiatric Epidemiology, 1996 - 1998
New York Presbyterian Hospital (Cornell Campus)Residency, Psychiatry, 1981 - 1985
Stony Brook University Health Sciences Center School of MedicineClass of 1981

PREvent First Episode Relapse (PREFER) Start of enrollment: 2004 Nov 01
Unknown status
Phase 4

PubMed

1669 citations
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
David B. Allison, Janet L. Mentore, Moonseong Heo, L.P. Chandler, Joseph C. Cappelleri
The American Journal of Psychiatry. 1999-11-01
37 citations
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
Marjie L. Hard, Richard J. Mills, Brian M. Sadler, Angela Wehr, Peter J. Weiden
CNS Drugs. 2017-07-01
312 citations
Obesity as a risk factor for antipsychotic noncompliance
Peter J. Weiden, Joan Mackell, Diana D. McDonnell
Schizophrenia Research. 2004-01-01

Journal Articles

Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends in Pharmacological Sciences (2022) https://doi.org/10.1016/j.tips.2022.09.006
Yohn SE, Weiden PJ, Felder CC & Stahl SM, Trends in Pharmacological Sciences (2022), 12/1/2022
Antipsychotic Efficacy of KarXT (Xanomeline− Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, ...
Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, & Paul SM, The Journal of Clinical Psychiatry, 83(3), 40913. (2022), 9/1/2022

Deep Sleep “Therapy” in Australia in the 1960s & ’70s: Could Something like This Happen Today?August 27th, 2020
Neuroleptic and Anti-Depressant Drugs: Akathisia, Suicide and ViolenceNovember 8th, 2016
How Clinicians Can Brush up on Emerging Schizophrenia DrugsOctober 11th, 2023

American Psychiatric Association - APA
Fellow
Schizophrenia International Research Society
Member
American Society of Clinical Psychopharmacology
Member
The International Society for CNS Clinical Trials and Methodology (ISCTM) 
Member